Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation

References

• Abbott DW, Freeman ML, Holt JT. 1998. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. Journal of the National Cancer Institute 90:978–985.
   PubMedGoogle Scholar
• Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. 1994. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. International Journal of Cancer 58:185–191.
   PubMed Web of Science ®Google Scholar
• Borden EC, Hogan TF, Voelkel JG. 1982. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Research 42:4948–4953.
   PubMed Web of Science ®Google Scholar
• Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248–254.
   PubMed Web of Science ®Google Scholar
• Branca AA, Baglioni C. 1981. Evidence that types I and II interferons have different receptors. Nature 294:768–770.
   PubMed Web of Science ®Google Scholar
• Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, et al 1991. Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Research 51:1294–1299.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, et al 1995. alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. International Journal of Cancer 61:342–347.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, et al 2003. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death and Differentiation 10:218–229.
   PubMed Web of Science ®Google Scholar
• Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD. 1996. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. The Journal of Biological Chemistry 271:33165–33168.
   PubMed Web of Science ®Google Scholar
• Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, et al 2003. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Annals of Surgical Oncology 10:1184–1190.
   PubMed Web of Science ®Google Scholar
• Fensterl V, Sen GC. 2009. Interferons and viral infections. Biofactors 35:14–20.
   PubMed Web of Science ®Google Scholar
• Fertil B, Dertinger H, Courdi A, Malaise EP. 1984. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiation Research 99:73–84.
   PubMed Web of Science ®Google Scholar
• Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al 1996. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Research 56:5360–5364.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Mosny SA. 1977. Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Research 37:1794–1799.
   PubMed Web of Science ®Google Scholar
• Holsti LR, Mattson K, Niiranen A, Standertskiold-Nordenstam CG, Stenman S, Sovijarvi A, et al 1987. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. International Journal of Radiation Oncology, Biology, Physics 13:1161–1166.
   PubMed Web of Science ®Google Scholar
• Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. 1992. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: Higher efficacy of interferon beta. Journal of the National Cancer Institute 84:1185–1190.
   PubMedGoogle Scholar
• Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW, Marten A. 2005. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World Journal of Gastroenterology 11:1521–1528.
   PubMed Web of Science ®Google Scholar
• Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine W, Mohiuddin M, et al 2002. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells. Anticancer Research 22:825–830.
   PubMed Web of Science ®Google Scholar
• Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. 1996. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110:1215–1224.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al 2001. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. The Lancet 358:1576–1585.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England Journal of Medicine 350:1200–1210.
   PubMed Web of Science ®Google Scholar
• Picozzi VJ, Kozarek RA, Traverso LW. 2003. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. American Journal of Surgery 185:476–480.
   PubMed Web of Science ®Google Scholar
• Posner MC, Gooding WE, Landreneau RJ, Rosenstein MM, Clarke MR, Peterson MS, et al 1998. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. The Cancer Journal from Scientific American 4:237–246.
   PubMed Web of Science ®Google Scholar
• Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. 1997. Interferon-beta induces S phase accumulation selectively in human transformed cells. Journal of Interferon & Cytokine Research 17:355–367.
   PubMed Web of Science ®Google Scholar
• Renart J, Reiser J, Stark GR. 1979. Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: A method for studying antibody specificity and antigen structure. Proceedings of the National Academy of Sciences of the USA 76:3116–3120.
   PubMed Web of Science ®Google Scholar
• Roos WP, Binder A, Bohm L. 2000. Determination of the initial DNA damage and residual DNA damage remaining after 12 hours of repair in eleven cell lines at low doses of irradiation. International Journal of Radiation Biology 76:1493–1500.
   PubMed Web of Science ®Google Scholar
• Saidi RF, Williams F, Ng J, Danquah G, Mittal VK, ReMine SG, et al 2006. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. American Journal of Surgery 191:358–363.
   PubMed Web of Science ®Google Scholar
• Schindler C, Darnell JE Jr. 1995. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annual Review of Biochemistry 64:621–651.
   PubMed Web of Science ®Google Scholar
• Schindler C, Plumlee C. 2008. Inteferons pen the JAK-STAT pathway. Seminars in Cell & Developmental Biology 19:311–318.
   PubMed Web of Science ®Google Scholar
• Schmidberger H, Rave-Frank M, Lehmann JJ, Weiss E, Gerl L, Dettmer N, et al 2003. Lack of interferon beta-induced radiosensitization in four out of five human glioblastoma cell lines. International Journal of Radiation Oncology, Biology, Physics 55:1348–1357.
   PubMed Web of Science ®Google Scholar
• Subramaniam PS, Johnson HM. 1997. A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. Journal of Interferon & Cytokine Research 17:11–15.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods 184:39–51.
   PubMed Web of Science ®Google Scholar
• Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, et al 2006. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Research 66:554–562.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Yoshida J, Mizuno M, Kito A, Sugita K. 1992. Effectiveness of interferon-beta, ACNU, and radiation therapy in pediatric patients with brainstem glioma. Neurologia Medico-Chirurgica 32:942–946.
   PubMedGoogle Scholar
• Williams BR, Haque SJ. 1997. Interacting pathways of interferon signaling. Seminars in Oncology 24:S9–70–S79–77.
   Web of Science ®Google Scholar